Reported about 1 month ago
Novavax Inc. experienced a significant drop in its stock price, falling by up to 24%, following the FDA's decision to place a hold on its experimental influenza and COVID-19 combination vaccines due to a serious adverse event reported by a study participant. The company, which previously gained prominence for its COVID-19 vaccine, is working with regulators to address the situation, while its stand-alone flu shots are also affected by the pause.
Source: YAHOO